Search results
Showing 1 to 15 of 17 results for semaglutide
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Awaiting development [GID-TA10438] Expected publication date: TBC
NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA910
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]
In development [GID-TA10834] Expected publication date: 22 May 2024
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Oral semaglutide for managing overweight and obesity [ID6188]
Awaiting development [GID-TA11149] Expected publication date: TBC
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis TS ID 11945
Awaiting development [GID-TA11477] Expected publication date: TBC
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....
This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults.
NICE committee recommends tirzepatide as new treatment option for people with type 2 diabetes
Around 180,000 people with difficult to manage type 2 diabetes could benefit from a new treatment option recommended by NICE
Digital services to enable easier access to weight management support
Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England, NICE has said in draft guidance.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use, a NICE committee has said.